Boston Scientific's third quarter matched Wall Street's adjusted EPS target, but the match says little about the quarter itself. Adjusted EPS of $0.73 equaled both the consensus estimate and the Earnings Whisper number. That was down 2.7% from a year ago and well short of the $0.80 to $0.82 the company had guided to only three months earlier. Revenue of $5.138 billion missed consensus by 0.6% and grew just 1.4% year over year. The company's own reported, operational and organic growth figures round to 1.5%. Its organic guide had called for 3% to 5%. The bigger news came after the quarter. Management cut full-year guidance for the fourth consecutive call, guided fourth-quarter revenue lower year over year, and framed 2027 as a year in which the company will be challenged to grow at all. That is the central development: a growth compounder is now being rebuilt as a reset story.
The quality of the quarter deserves scrutiny. Management attributed roughly 300 basis points of revenue and about $0.07 of EPS to the August cybersecurity incident, which caused a roughly two-week outage. Taken alone, that suggests underlying results were near the guided range. But the cyber event does not explain everything. Electrophysiology fell 5% (U.S. down 8%), after growing 22% in the first quarter and 9% in the second. Watchman declined 6%, with U.S. standalone procedures down in the high teens. Urology fell 3%, endoscopy 1%, CRM 2%, and Asia-Pacific slipped 1% operationally as China volume-based procurement broadened. Profitability also weakened. Adjusted gross margin fell 300 basis points to 68.0%, versus 70.3% in the second quarter, and operating margin dropped 150 basis points to 26.5%. On a GAAP basis, EPS fell to $0.40 from $0.51. Restructuring, litigation and impairment charges all rose from a year ago.
There were genuine bright spots. Interventional cardiology grew 19%, accelerating from 15% in the second quarter and 9% in the first, with the Agent drug-coated balloon past 400,000 patients. Neuromodulation grew 13%, EMEA improved to 6% operational growth, and U.S. Watchman concomitant procedures rose about 35%. Those pockets of strength are not large enough to offset share erosion in pulsed field ablation. Management said the incident accelerated that erosion and expects it to continue until Farawave Ultra launches. That launch has now slipped to early 2028, with Faraflex pushed to 2029. Roughly six-month delays now run across several platforms, including slower renal denervation enrollment.
The forward picture is where the damage concentrates. Full-year organic growth guidance now stands at about 3.75%, down from 10% to 11% at the start of the year. Adjusted EPS guidance has been cut to $3.16 to $3.18 from $3.43 to $3.49. Operating margin is now expected to contract to about 27.6%, versus the 50 to 75 basis points of expansion originally promised. Free cash flow guidance has dropped to roughly $3.6 billion from $4.2 billion. Fourth-quarter revenue is guided down 1% to 3%, with another $0.04 to $0.05 of EPS lost to cyber-related customer destocking. Management also flagged several 2027 risks:
- significant gross margin pressure from mix and China pricing
- a new Watchman competitor
- a Penumbra close delayed to early 2027, with dilution likely higher on interest rates
On the positive side, catalysts include a Blackstone co-funding deal that moves Vitalist R&D off the income statement, multiple urology and peripheral approvals, and restructuring savings above $500 million tracking slightly ahead of plan. Management openly acknowledged it must rebuild forecasting credibility.
Investors had already moved toward that view. Earnings Whispers sentiment fell to -0.51 from -0.27 at the prior report, a meaningful deterioration from mildly to decidedly negative. The stock's path tells the same story. Shares peaked at $52.99 in mid-August, just before the cyber incident was disclosed. They then slid to a 52-week low of $41.39 on October 8. Heading into the report, they stood at $45.06. That was 5.6% above the open following the July report but 21.6% below the $57.50 200-day moving average. The stock had bounced off its lows, so some recovery hopes were embedded before this guide. Earnings Whispers momentum and AVWAP trend readings remain negative.
The bottom line is that Boston Scientific delivered an in-line headline that masks a deteriorating operating picture. Core franchises are losing share, margins are compressing and the pipeline is slipping. Interventional cardiology, neuromodulation and the restructuring program preserve a credible long-term foundation. But with the fourth quarter positioned as the baseline and 2027 described as a no-growth trough, bears have legitimate ammunition, and management now has to prove its guidance before investors extend it the benefit of the doubt.